Adverum Biotechnologies, Inc. reports developments as a clinical-stage biotechnology company focused on intravitreal gene therapy for ocular diseases. Its updates center on ixoberogene soroparvovec, or Ixo-vec, a one-time intravitreal candidate for neovascular, or wet, age-related macular degeneration, including ARTEMIS Phase 3 trial communications and clinical or regulatory disclosures.
Recurring news also includes operating and financial results, inducement equity awards under Nasdaq Listing Rule 5635(c)(4), material agreements, capital-structure matters, shareholder and governance disclosures, and corporate transaction communications.
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.27%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
FAQ
What is the current stock price of Adverum Biotechnologies (ADVM)?
The current stock price of Adverum Biotechnologies (ADVM) is $4.36 as of December 9, 2025.
What is the market cap of Adverum Biotechnologies (ADVM)?
The market cap of Adverum Biotechnologies (ADVM) is approximately 91.5M.